Inovio Pharmaceuticals
214 hedge funds and large institutions have $1.52B invested in Inovio Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 92 funds opening new positions, 73 increasing their positions, 31 reducing their positions, and 34 closing their positions.
366% more capital invested
Capital invested by funds: $327M → $1.52B (+$1.2B)
171% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 34
135% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 31
35% more funds holding
Funds holding: 158 → 214 (+56)
17% more call options, than puts
Call options by funds: $269M | Put options by funds: $230M
0.47% more ownership
Funds ownership: 2.52% → 2.98% (+0.47%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$71.4M |
| 2 |
BlackRock
New York
|
+$69M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.4M |
| 4 |
Coatue Management
New York
|
+$36.8M |
| 5 |
Jane Street
New York
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$28.5M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$28.4M |
| 3 |
VA
VR Adviser
New York
|
-$21.6M |
| 4 |
Millennium Management
New York
|
-$21.1M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$19.9M |
INO Hedge Fund Activity: Q2 2020 in Review
214 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2020, worth a combined $1.52B — up 366% from $327M a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new INO positions and 34 closed out — a net gain of 58 holders — while 73 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $71.4M. The largest seller was Nikko Asset Management Americas, cutting an estimated $28.5M.
- 214 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2020, up from 158 in Q1 2020.
- Funds reported $1.52B of Inovio Pharmaceuticals stock for Q2 2020, up 366% quarter-over-quarter.
- 92 funds opened new Inovio Pharmaceuticals positions in Q2 2020 and 34 closed out, a net change of +58 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2020 was State Street, an estimated $71.4M added.
- The largest Inovio Pharmaceuticals seller in Q2 2020 was Nikko Asset Management Americas, an estimated $28.5M sold.
Based on aggregated 13F filings for Q2 2020.